Recent Medical press releases & news

Presswire is the leading news platform where businesses, educational institutions, news reporters, etc. come together to share compelling news stories that transform opinions and impact lives. Presswire has an extensive media contact list for press releases, reaching millions of contacts. We ensure that your story lands on the right business desks and the right mass media outlets. To begin your press release distribution, send your stories to Presswire or by filling out the form here.

1

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA —May 17, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today its participation at the Neuro4D International Conference, held at the Atrium Hotel, Mainz, Germany, May 16-17th.

1

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 13, 2022 – There was an error at the end of the first paragraph.  March 31, 2021 has been changed to March 31, 2022.  There were no other changes to the release.  Please find full corrected release below.

1

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – May 13, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce the Annual and Special Meeting of Shareholders (the “Meeting”) of ProMIS was held online by virtual web-cast meeting, on Thursday, May 12, 2022 at 9:00 a.m. (Pacific time).

1

 

[PRESSWIRE] Asia - 03.05.22 -- In South Korea, in cooperation with Heavenly Culture, World Peace and Restoration of Light (HWPL), 18,000 members of Shincheonji Church of Jesus and HWPL participated in blood donation for two weeks from April 18th. This number was recorded as the largest group blood donation in the country.

1

 

[PRESSWIRE] LUBBOCK, TX -- April 19, 2022 – NemaLife Inc., a DEA-registered and innovation-driven techbio company, has partnered with the research group led by Professor David E. Olson at the University of California, Davis to characterize the in vivo effects of several of their novel psychoplastogens.

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. April 19, 2022 - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has appointed Larry Altstiel M.D. Ph.D., as Chief Medical Officer.

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA — [April 7, 2022] — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it has presented at the  American Academy of  Neurology (AAN) Annual Meeting held at the Washington State Convention Center in Seattle, April 2-7, 2022.

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Massachusetts – April 07, 2022 – ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF) (“ProMIS” or the “Corporation”), is pleased to announce it has mailed the Notice of Notice-and-Access (the “N&A Notice”) to shareholders of record of the Corporation as of April 01, 2022, in connection with the Annual General and Special Meeting of the Shareholders (the “Meeting”) of the Corporation to be held Thursday, May 12, 2022, at 9:00 a.m. (Pacific Time). 

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, MA —March 24, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today that it will be presenting at the upcoming 10th Annual Neurodegenerative Drug Development Summit, to be held in Boston, MA, March 28-30, 2022.

 

[PRESSWIRE] TORONTO, Ontario and CAMBRIDGE, Mass. —March 22, 2022 — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of therapeutics targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases, announced today in vivo results of its experimental Alzheimer’s vaccine presented at the AD/PDTM International Conference held in Barcelona Spain, March 15-20, 2022.